Tagged with P

USA While the year’s tally of green lights from the FDA’s Center for Drug Evaluation and Research (CDER) is lower than the previous year’s, 2024 saw several long-awaited therapies reach the finish line. Oncology remained the single largest focus area among last year’s endorsed therapies and as opposed to 2023 when…

Saudi Arabia AstraZeneca has made remarkable progress over the past three years in Saudi Arabia, gaining significant leadership in therapeutic areas like oncology and respiratory care, and expansion into rare diseases. Sameh ElFangary, Country President of AstraZeneca GCC & Pakistan shares insights into the company’s strategy and strong alignment with Saudi Arabia’s…

Puerto Rico Gustavo A. Hermida, President of CIC Construction Group, shares the remarkable journey of Puerto Rico’s leading general contractor. Built on a foundation of excellence in the pharmaceutical sector, CIC has successfully diversified into healthcare, hospitality, and housing while upholding its rigorous standards of safety, quality, and timely delivery. Hermida highlights…

Global With a record number of recent approvals representing game-changing potential for conditions like sickle cell disease, a significant number of advanced therapies making progress in the clinic, and an uptick in investment, cell and gene therapies are set to continue making considerable headway in 2025. Yet their elevated price tag…

Germany A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’ withdrawal from purchase of Evotec; Merck KGaA-controlled MilliporeSigma’s acquisition of HUB Organoids, and Gilead’s USD 465 million solid tumour deal…

Europe The Women’s Brain Foundation, formerly the Women’s Brain Project, has evolved into a fully-fledged foundation dedicated to advancing research in gender precision medicine with a strong focus on brain health. CEO pro-bono Dr Antonella Santuccione Chadha comments on the organisation’s newly extended global reach, progress in understanding the link between…

CEE A roundup of some of the top news coming out of the Central and Eastern European (CEE) region’s pharma industry, including Poland’s first draft of a national critical medicines list; Polpharma’s acquistion of the dermatological firm Ziołolek; Sopharma’s sale of its logistics unit, Farmalogistika; Horus Pharma’s significant stake in Romania’s…

Puerto Rico Migna Fontan, Director of Operations for Viant Medical in Puerto Rico, provides insights into the company’s evolution and its critical role in the medtech industry. Fontan discusses Viant’s journey in Puerto Rico, its transformative milestones, and its manufacturing facility’s innovative capabilities. She highlights how the island’s skilled workforce positions Puerto…

China Since raising USD 289 million in its Spring 2020 Hong Kong IPO, InnoCare Pharma has had a remarkable rise. Led by a team of Big Pharma veterans and now also listed in Shanghai, the firm has secured regulatory approvals for its BTK inhibitor for haematological cancers in mainland China and…

China Eye health, despite being essential for most of us in our daily lives, receives significantly less research funding than fields like cancer or diabetes. According to IQVIA, global spending on oncology is expected to reach USD 440 billion by 2028, while ophthalmology will see just USD 38 billion. However, conditions…

China There are over 7,000 different rare diseases globally, many of which affect only a handful of patients. However, given the scale of China’s population, rare diseases in the country take on an increased significance, something that Chinese policymakers have worked to address in recent years.   “China now introduces new…

China While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life sciences ecosystem. Eased restrictions on foreign investment have made it even more attractive for international pharma while China’s native innovators…